Therapeutic schemes to combat Covid-19: systematic review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/11533 |
Resumo: | The aim of this study was to investigate the main therapeutic regimens used so far in the Covid-19 fight on the world stage. Is a systematic literature review conducted in ScienceDirect, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) and Scientific Electronic Library Online (SciELO) databases, using the term “treatment Covid-19”, carried out in April 2020. We selected 16 articles according to the inclusion criteria: research articles, published between February 2019 and April 2020, without distinction of languages. The work was organized according to PRISMA recommendations, registered in PROSPERO. The articles found, ranged from in vitro, in silico, open clinical trials, cohort, retrospective and analytical, and were conducted in China, France, India, Saudi Arabia and South Korea, with the highest number of Chinese publications (70.5%). Samples range from one to 199 people, all infected with the SARS-CoV-2 virus, with a higher percentage of females (51.7%), ages 18 to 88 years. Medicines like lopinavir, ritonavir, favipiravir, arbidol, costicoteroids, hydroxychloroquine, recipes of traditional Chinese medicine, glycirrizine, azithromycin, and tocilizumab were analyzed in studies in a monotherapeutic or associated form, as well as mesenchyhimsal stem cell transplantation, intensive plasma exchange and intravenous immunoglobulin. There were divergences and complementation of results among the authors. Despite presenting findings and assisting in the fight against the pandemic, current studies present promising drugs for the treatment of symptomatology and viral load, with the objective of identifying an ideal treatment for the disease, not obtaining consensus. |
id |
UNIFEI_40e2f3a38a95b706335b6801e6fe5598 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/11533 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Therapeutic schemes to combat Covid-19: systematic reviewEsquemas terapéuticos para combatir Covid-19: revisión sistemáticaEsquemas terapêuticos para combate da Covid-19: revisão sistemáticaCOVID-19SARS-CoV-2Clinical managementAntiviral drugs.COVID-19SARS-CoV-2Gestión clínicaMedicamentos antivirales.COVID-19SARS-Cov-2Manejo clínicoDrogas antivirais.The aim of this study was to investigate the main therapeutic regimens used so far in the Covid-19 fight on the world stage. Is a systematic literature review conducted in ScienceDirect, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) and Scientific Electronic Library Online (SciELO) databases, using the term “treatment Covid-19”, carried out in April 2020. We selected 16 articles according to the inclusion criteria: research articles, published between February 2019 and April 2020, without distinction of languages. The work was organized according to PRISMA recommendations, registered in PROSPERO. The articles found, ranged from in vitro, in silico, open clinical trials, cohort, retrospective and analytical, and were conducted in China, France, India, Saudi Arabia and South Korea, with the highest number of Chinese publications (70.5%). Samples range from one to 199 people, all infected with the SARS-CoV-2 virus, with a higher percentage of females (51.7%), ages 18 to 88 years. Medicines like lopinavir, ritonavir, favipiravir, arbidol, costicoteroids, hydroxychloroquine, recipes of traditional Chinese medicine, glycirrizine, azithromycin, and tocilizumab were analyzed in studies in a monotherapeutic or associated form, as well as mesenchyhimsal stem cell transplantation, intensive plasma exchange and intravenous immunoglobulin. There were divergences and complementation of results among the authors. Despite presenting findings and assisting in the fight against the pandemic, current studies present promising drugs for the treatment of symptomatology and viral load, with the objective of identifying an ideal treatment for the disease, not obtaining consensus.El objetivo de este estudio era investigar los principales regímenes terapéuticos utilizados hasta ahora en la lucha contra Covid-19 en la escena mundial. Es una revisión sistemática de la literatura realizada en las bases de datos ScienceDirect, Latin American Literature in Health Sciences (Lilacs) y Scientific Electronic Library Online (SciELO), utilizando el término "tratamiento Covid-19", celebrado en abril de 2020. Seleccionamos 16 artículos según los criterios de inclusión: artículos de investigación, publicados entre febrero de 2019 y abril de 2020, sin distinción de idiomas. El trabajo se organizó de acuerdo con las recomendaciones de prisma, registradas en PROSPERO. Los artículos encontrados iban desde ensayos clínicos in vitro, en silicio, abierto, cohorte, retrospectivo y analítico realizados en China, Francia, India, Arabia Saudita y Corea del Sur, con el mayor número de publicaciones chinas (70,5%). Las muestras oscilaron entre una y 199 personas, todas infectadas con SARS-CoV-2, con un mayor porcentaje de mujeres (51,7%), de 18 a 88 años. Se analizaron medicamentos como lopinavir, ritonavir, favipiravir, arbidol, costicoteroides, hidroxicloroquina, recetas de medicina tradicional china, glicirina, azitromicina y tocilizumab en estudios en forma monoterapéutica o asociada, así como trasplante de células madre mesénquipales, intercambio plasmático intensivo e inmunoglobulina intravenosa. Hubo divergencias y complementación de los resultados entre los autores. A pesar de presentar los hallazgos y ayudar en la lucha contra la pandemia, los estudios presentan fármacos prometedores para el tratamiento de la sintomatología y la carga viral, con el objetivo de identificar la terapia ideal para la enfermedad, no obtener consenso.O objetivo deste estudo foi investigar os principais esquemas terapêuticos utilizados até o momento no combate da Covid-19 no cenário mundial. É uma revisão sistemática de literatura realizada nas bases ScienceDirect, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) e Scientific Electronic Library Online (SciELO), utilizando o termo “treatment Covid-19”, realizada no mês de abril de 2020. Foram selecionados 16 artigos, segundo os critérios de inclusão: artigos de pesquisa, publicados entre fevereiro de 2019 a abril de 2020, sem distinção de idiomas. O trabalho foi organizado de acordo com as recomendações PRISMA, registrado no PROSPERO (CRD42020186262). Os artigos encontrados, variaram de estudos in vitro, in silico, ensaios clínicos abertos, coorte, retrospectivos e analíticos, realizados na China, na França, na Índia, na Arábia Saudita e na Coreia do Sul, com maior número de publicações chinesas (70,5%). As amostras variaram de uma a 199 pessoas, todas infectadas com o SARS-CoV-2, com maior percentual do sexo feminino (51,7%), idades entre 18 a 88 anos. Medicamentos como lopinavir, ritonavir, favipiravir, arbidol, costicoteroides, hidroxicloroquina, receitas da medicina tradicional chinesa, glicirrizina, azitromicina e tocilizumabe foram analisados nos estudos de forma monoterápica ou associados entre si, assim como transplante de células tronco mesenquimais, troca plasmática intensiva e imunoglobulina intravenosa. Houve divergências e complementação de resultados entre os autores. Apesar de apresentarem descobertas e auxiliarem no combate à pandemia, os estudos apresentam drogas promissoras para o tratamento da sintomatologia e carga viral, com o objetivo de identificar a terapia ideal para a doença, não obtendo consenso.Research, Society and Development2021-01-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1153310.33448/rsd-v10i1.11533Research, Society and Development; Vol. 10 No. 1; e21310111533Research, Society and Development; Vol. 10 Núm. 1; e21310111533Research, Society and Development; v. 10 n. 1; e213101115332525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/11533/10421Copyright (c) 2021 Danielli Marinho Zuil; Volmar Morais Fontoura; Floriacy Stabnow Santos; Marcelino Santos Neto; Lívia Maia Pascoal; Márcia Caroline Nascimento Sá Ewerton Martins; Maikon Graepp Fontoura; Alzira Regina Dantas Dias; Cynthia Cardozo Dias Lima; Iolanda Graepp-Fontourahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessZuil, Danielli Marinho Fontoura, Volmar Morais Santos, Floriacy Stabnow Santos Neto, MarcelinoPascoal, Lívia Maia Martins, Márcia Caroline Nascimento Sá Ewerton Fontoura, Maikon Graepp Dias, Alzira Regina Dantas Lima, Cynthia Cardozo Dias Graepp-Fontoura, Iolanda2021-02-20T21:19:23Zoai:ojs.pkp.sfu.ca:article/11533Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:33:19.958276Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Therapeutic schemes to combat Covid-19: systematic review Esquemas terapéuticos para combatir Covid-19: revisión sistemática Esquemas terapêuticos para combate da Covid-19: revisão sistemática |
title |
Therapeutic schemes to combat Covid-19: systematic review |
spellingShingle |
Therapeutic schemes to combat Covid-19: systematic review Zuil, Danielli Marinho COVID-19 SARS-CoV-2 Clinical management Antiviral drugs. COVID-19 SARS-CoV-2 Gestión clínica Medicamentos antivirales. COVID-19 SARS-Cov-2 Manejo clínico Drogas antivirais. |
title_short |
Therapeutic schemes to combat Covid-19: systematic review |
title_full |
Therapeutic schemes to combat Covid-19: systematic review |
title_fullStr |
Therapeutic schemes to combat Covid-19: systematic review |
title_full_unstemmed |
Therapeutic schemes to combat Covid-19: systematic review |
title_sort |
Therapeutic schemes to combat Covid-19: systematic review |
author |
Zuil, Danielli Marinho |
author_facet |
Zuil, Danielli Marinho Fontoura, Volmar Morais Santos, Floriacy Stabnow Santos Neto, Marcelino Pascoal, Lívia Maia Martins, Márcia Caroline Nascimento Sá Ewerton Fontoura, Maikon Graepp Dias, Alzira Regina Dantas Lima, Cynthia Cardozo Dias Graepp-Fontoura, Iolanda |
author_role |
author |
author2 |
Fontoura, Volmar Morais Santos, Floriacy Stabnow Santos Neto, Marcelino Pascoal, Lívia Maia Martins, Márcia Caroline Nascimento Sá Ewerton Fontoura, Maikon Graepp Dias, Alzira Regina Dantas Lima, Cynthia Cardozo Dias Graepp-Fontoura, Iolanda |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Zuil, Danielli Marinho Fontoura, Volmar Morais Santos, Floriacy Stabnow Santos Neto, Marcelino Pascoal, Lívia Maia Martins, Márcia Caroline Nascimento Sá Ewerton Fontoura, Maikon Graepp Dias, Alzira Regina Dantas Lima, Cynthia Cardozo Dias Graepp-Fontoura, Iolanda |
dc.subject.por.fl_str_mv |
COVID-19 SARS-CoV-2 Clinical management Antiviral drugs. COVID-19 SARS-CoV-2 Gestión clínica Medicamentos antivirales. COVID-19 SARS-Cov-2 Manejo clínico Drogas antivirais. |
topic |
COVID-19 SARS-CoV-2 Clinical management Antiviral drugs. COVID-19 SARS-CoV-2 Gestión clínica Medicamentos antivirales. COVID-19 SARS-Cov-2 Manejo clínico Drogas antivirais. |
description |
The aim of this study was to investigate the main therapeutic regimens used so far in the Covid-19 fight on the world stage. Is a systematic literature review conducted in ScienceDirect, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) and Scientific Electronic Library Online (SciELO) databases, using the term “treatment Covid-19”, carried out in April 2020. We selected 16 articles according to the inclusion criteria: research articles, published between February 2019 and April 2020, without distinction of languages. The work was organized according to PRISMA recommendations, registered in PROSPERO. The articles found, ranged from in vitro, in silico, open clinical trials, cohort, retrospective and analytical, and were conducted in China, France, India, Saudi Arabia and South Korea, with the highest number of Chinese publications (70.5%). Samples range from one to 199 people, all infected with the SARS-CoV-2 virus, with a higher percentage of females (51.7%), ages 18 to 88 years. Medicines like lopinavir, ritonavir, favipiravir, arbidol, costicoteroids, hydroxychloroquine, recipes of traditional Chinese medicine, glycirrizine, azithromycin, and tocilizumab were analyzed in studies in a monotherapeutic or associated form, as well as mesenchyhimsal stem cell transplantation, intensive plasma exchange and intravenous immunoglobulin. There were divergences and complementation of results among the authors. Despite presenting findings and assisting in the fight against the pandemic, current studies present promising drugs for the treatment of symptomatology and viral load, with the objective of identifying an ideal treatment for the disease, not obtaining consensus. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-01-08 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/11533 10.33448/rsd-v10i1.11533 |
url |
https://rsdjournal.org/index.php/rsd/article/view/11533 |
identifier_str_mv |
10.33448/rsd-v10i1.11533 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/11533/10421 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 1; e21310111533 Research, Society and Development; Vol. 10 Núm. 1; e21310111533 Research, Society and Development; v. 10 n. 1; e21310111533 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052744289222656 |